Oncolytics Biotech receives Canadian patent for treating cellular proliferative disorders

New York, Oct. 7 - Oncolytics Biotech Inc. said it received Canadian patent 2,428,206 covering a treatment for cellular proliferative disorders including neurofibromatosis and neoplasms using various strains of the reovirus.

"The claims in Oncolytics' second Canadian patent provide broad coverage for the use of reovirus in treating cellular proliferative disorders including cancers," said Matt Coffey, Oncolytics' chief scientific officer, in a news release. "This patent complements existing intellectual property coverage of reovirus for the treatment of various human cancers in the U.S., Europe and worldwide."

Oncolytics Biotech is a Calgary, Alta., biotechnology company working on a proprietary formulation of the human reovirus as a potential cancer therapeutic.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.